Back to Authors

Donald, Elena M

0000-0002-2232-5688

Mayo Clinic

Columbia University Irving Medical Center

Citations 1

Mitigating Risk of Kidney Dysfunction After Heart Transplantation and Therapeutic Approaches
DeFilippis, Ersilia M. , Cheng, Richard K., Donald, E., Dunlay, Shannon M. , Evangelista, Lorraine S. , Kamdar, Forum , Khazanie, Prateeti , Mohammed, Selma F. , Rossi, Ana P. , Spall, Harriette G.C. Van , Breathett, Khadijah , Cheng, Richard K. , DeFilippis, Ersilia M. , Donald, Elena M , Van Spall, Harriette G C , Verma, Aradhana , Breathett, Khadijah , Dunlay, Shannon , Cheng, Richard , Mohammed, Selma , Rossi, Ana

Circulation: Heart Failure | February 24, 2026 | Volume: 19 | Issue: 4 | Pages: No page available

10.1161/circheartfailure.125.013747 Get It

Kidney dysfunction after heart transplantation (HT) is associated with significant morbidity and mortality. Recipient and perioperative factors may all influence the risk of kidney injury. Furthermore, data suggest that the incidence of kidney dysfunction, both acute and chronic, is increasing after the implementation of the United States’ 2018 allocation system due to increasing use of temporary mechanical circulatory support and changing recipient characteristics. While data are robust regarding nephroprotective therapies such as renin-angiotensin-aldosterone system inhibition and SGLT2i (sodium-glucose cotransporter 2 inhibitors) to minimize the progression of chronic kidney disease in patients with heart failure, data in HT recipients are beginning to emerge. This state-of-the-art review will critically examine the existing literature regarding the epidemiology of kidney dysfunction after HT, mitigation strategies for acute kidney injury and chronic kidney disease, including pharmacotherapeutics, the need for kidney transplantation after HT, and practical next steps for the larger HT community.